European Medicines Agency
Pre-Authorisation Evaluation of Medicines for Human Use

London, 19 March 2009
Doc.Ref. EMEA/CHMP/153867/2009

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE
SUMMARY OF POSITIVE OPINION[*]
for
NIMVASTID

International Nonproprietary Name (INN): ***rivastigmine***

On 19 March the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion[**], recommending the granting of a marketing authorisation for the medicinal product Nimvastid 1.5 mg, 3 mg, 4.5 mg, 6 mg hard capsules and Nimvastid 1.5 mg, 3 mg, 4.5 mg, 6 mg Orodispersible tablets intended for the symptomatic treatment of mild to moderately severe Alzheimer's dementia and of mild to moderately severe dementia in patients with idiopathic Parkinson's disease. The applicant for this medicinal product is Krka, d.d., Novo mesto.

The active substance of Nimvastid is rivastigmine an anticholinesterases medicinal product *(*N06DA03*)*.
Nimvastid is a generic of Exelon, which has been authorised in the EU since 12 May 1998. Studies have demonstrated the satisfactory quality of Nimvastid, and its bioequivalence with Exelon. A question-and-answer document on generic medicines can be found here.

The approved indication is: "Rivastigmine is indicated for the symptomatic treatment of of mild to moderately severe Alzheimer's dementia and mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

Detailed recommendations for the use of this product will be described in the Summary of Product Characteristics (SPC) which will be published in the European Public Assessment Report (EPAR) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CHMP, on the basis of the data submitted, considers that there is a favourable benefit risk balance for Nimvastid, and therefore recommends the granting of the marketing authorisation.

[*] Summaries of positive opinion are published without prejudice to the Commission Decision, which will normally be issued within 67 days from adoption of the Opinion.

[**] Applicants may request a re-examination of any CHMP opinion, provided they notify the EMEA in writing of their intention to request a re-examination within 15 days of receipt of the opinion.

7 Westferry Circus, Canary Wharf, London E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 7182
E-mail: mail@emea.europa.eu http://www.emea.europa.eu
© European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged.